Neuraxis, INC (NRXS) stock
Close on Nov 16, 2026Market cap $60.28MP/E –Yield –
Neuraxis, INC grew revenue 65.2% to $5.32M over the twelve months to Jun 30, 2026. Free cash flow was -$6.46M. At the latest close the market valued the company at $60.28M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $60.28M
- P/E ratio
- –
- Price to sales
- 11.34
- Price to book
- 8.95
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $5.32M
- Net income
- -$7.68M
- EPS, diluted
- -$0.79
- Free cash flow
- -$6.46M
- Book value per share
- $0.56
- Diluted shares
- 12M
Trading
- Previous close
- $5.42
- Open
- $5.30
- Day's range
- $4.71 – $5.42
- Volume
- 521,424
- Average volume (20 days)
- 138,860
- 52-week range
- $2.21 – $9.33
- RSI (14 days)
- 27.1
- Volatility (1 year)
- 74.9%
- Relative volume
- 4.23×
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | NRXS | S&P 500 | Difference | NRXS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -37.7% | -3.1% | −34.6 pts | ||
| 3 months | -23.8% | -4.5% | −19.4 pts | ||
| Year to date | +5.7% | +9.4% | −3.6 pts | ||
| 1 year | +105.1% | +11.3% | +93.8 pts | ||
| 3 years | +87.9% | +70.4% | +17.5 pts | +23.4% | +19.4% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Neuraxis filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Results
- Results
- Results
- Results
About Neuraxis
Electromedical & Electrotherapeutic Apparatus
Neuraxis, Inc. is a medical technology company that develops neuromodulation therapies for chronic and debilitating conditions of the gastrointestinal digestive system caused by disorders of gut-brain interaction. Its primary offering is IB-Stim, a proprietary Percutaneous Electrical Nerve Field Stimulation medical device cleared by the FDA to treat functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms in patients eight years of age and older. The company also offers the Rectal Expulsion Device, which evaluates rectal neuromuscular function and tests for rectal hypersensitivity in adults. Target customers include pediatric and adult patients treated by pediatricians, pediatric gastroenterologists, and trained healthcare providers in clinical settings.
Company profile, executives and historyNeuraxis stock: common questions
What is Neuraxis's stock price?
NRXS closed at $4.80 on Nov 16, 2026, down 11.44% on the day. Over the past 52 weeks it traded between $2.21 and $9.33.
What is Neuraxis's market cap?
Neuraxis was worth $60.28M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is NRXS's P/E ratio?
Neuraxis lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.79), so it has no meaningful P/E ratio.
How much revenue does Neuraxis make?
Neuraxis reported revenue of $5.32M for the twelve months to Jun 30, 2026, up 65.2% from a year earlier.
Does Neuraxis pay a dividend?
No. Neuraxis has not paid a cash dividend over the last twelve months.
How has NRXS stock performed over the past year?
Including dividends, NRXS returned +105.1% over the past year, against +11.3% for the S&P 500.
How many NRXS shares are sold short?
0M shares were sold short at the latest FINRA report, 6.04% of the float, or 4.4 days of average trading volume.
Who are Neuraxis's competitors?
Companies most similar to Neuraxis by business, industry and size include NMTC, NUWE, CV, ECOR, EBRCZ.
See a number that looks wrong?